You are here

Design of an Interactive Incentive Spirometer for Enhanced Respiratory Care

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AT007736-01A1
Agency Tracking Number: R43AT007736
Amount: $217,059.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCCAM
Solicitation Number: PA12-088
Timeline
Solicitation Year: 2013
Award Year: 2013
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
1200 Columbia Ave.
RIVERSIDE, CA 92507-
United States
DUNS: 68694962
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 DAVID TSAI
 (951) 788-9688
 davidtsai@ambryxbio.com
Business Contact
 HELEN CHEN
Phone: (951) 231-2106
Email: helenchen@ambryxbio.com
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): Cancer and rheumatoid arthritis (RA) share remarkably similar pathogenic pathways. For example, in both cancer and RA, angiogenesis, chronic inflammation and reactive oxygen species create a negative feedback loop thataccelerates disease progression. In the synovium of RA patients, fibroblast-like synoviocytes (RA- FLS) has features of tumor-like transformation including anchorage-independent growth, adhesion to the extracellular matrix of cartilage, resistance to apoptotic signaling, and invasiveness to cartilage and bone. We have isolated a novel milk peptide mixture (AX-3) that inhibits the tyrosine kinase activity of epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor 2 (VEGFR2), andinsulin receptor (IR). In vivo, AX-3 exhibits anti-cancer activity, increases the level of antioxidant enzyme Superoxide Dismutase, and reduces pro-inflammatory factors TNF-alpha, MCP-1, and RANTES. Recently, we further identified the active component of AX-3. These recent data and the understanding that inflammation, angiogenesis, hyperplasia, and oxidative stress are crucial mediators of RA led us to investigate the potential of AX-3 and its active component as therapeutic candidates for treating rheumatoid arthritis. In Specific Aim 1, AX-3 and its active component will be tested for their ability to induce apoptosis in RA-FLS. At lower dosages, the peptides will be assessed for inhibition of pro-inflammatory factor expressions in RA-FLS, and inhibition of several signaling pathways will also be tested. In Specific Aim 2, the in vivo effects of AX-3 and its active component on joint degradation and various biomarkers will be assessed using a collagen- induced RA rat model. In phase II study we will continue further molecular characterization and pharmacological studies based on the preliminary in vitro and animal results. The long term goal of this project is to develop a safe, effective, and cost-efficient therapy to treat RA. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Rheumatoid arthritis (RA) is an autoimmune joint disease that affects approximately 1% of the population. In addition to disability and decreased quality of life RA decreases life expectancy, most commonly from accelerated atherosclerosis. This study will investigate the feasibility of a milk-based substance's ability to slow the progression of RA by reducing inflammation and cartilage breakdown.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government